Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLOV Stock Forecast 2026-2027
$3.83
Current Price
$2.02B
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to CLOV Price Targets
+9.7%
To High Target of $4.20
-8.6%
To Median Target of $3.50
-28.2%
To Low Target of $2.75
CLOV Price Momentum
-2.3%
1 Week Change
+22.8%
1 Month Change
+25.2%
1 Year Change
+63.0%
Year-to-Date Change
-9.5%
From 52W High of $4.23
+142.4%
From 52W Low of $1.58
📊 TOP ANALYST CALLS
Did CLOV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Clover Health is one of their latest high-conviction picks.
Latest CLOV Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, CLOV has a neutral consensus with a median price target of $3.50 (ranging from $2.75 to $4.20). The overall analyst rating is Buy (7.3/10). Currently trading at $3.83, the median forecast implies a -8.6% downside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Richard Close at Canaccord Genuity, projecting a 9.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLOV Analyst Ratings
1
Buy
2
Hold
0
Sell
CLOV Price Target Range
Low
$2.75
Average
$3.50
High
$4.20
Current: $3.83
Latest CLOV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLOV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 4, 2026 | Canaccord Genuity | Richard Close | Buy | Maintains | $4.20 |
| Mar 20, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 5, 2026 | Leerink Partners | Market Perform | Maintains | $N/A | |
| Jan 20, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 6, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 7, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 6, 2025 | UBS | Neutral | Maintains | $N/A | |
| Mar 3, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 17, 2024 | Craig-Hallum | Buy | Initiates | $N/A | |
| Oct 7, 2024 | UBS | Neutral | Initiates | $N/A | |
| Aug 11, 2023 | Citigroup | Neutral | Maintains | $N/A | |
| Mar 6, 2023 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 6, 2023 | Credit Suisse | Underperform | Maintains | $N/A | |
| Nov 16, 2022 | Citigroup | Neutral | Maintains | $N/A | |
| Nov 8, 2022 | SVB Leerink | Market Perform | Maintains | $N/A | |
| Aug 9, 2022 | Citigroup | Neutral | Maintains | $N/A | |
| Aug 9, 2022 | Credit Suisse | Underperform | Maintains | $N/A | |
| May 10, 2022 | SVB Leerink | Market Perform | Maintains | $N/A | |
| Feb 25, 2022 | SVB Leerink | Market Perform | Maintains | $N/A | |
| Feb 2, 2022 | Canaccord Genuity | Buy | Initiates | $N/A |
Clover Health Investments, Corp. (CLOV) Competitors
The following stocks are similar to Clover Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CLOV
Clover Health
mkt cap
2.02B
Clover Health Investments, Corp. (CLOV) Financial Data
Clover Health Investments, Corp. has a market capitalization of $2.02B with a P/E ratio of -22.5x. The company generates $2.21B in trailing twelve-month revenue with a -2.6% profit margin.
Revenue growth is +62.0% quarter-over-quarter, while maintaining an operating margin of +3.6% and return on equity of -16.9%.
Valuation Metrics
Market Cap
$2.02B
Enterprise Value
$1.81B
P/E Ratio
-22.5x
PEG Ratio
0.0x
Price/Sales
0.9x
Growth & Margins
Revenue Growth (YoY)
+62.0%
Gross Margin
+21.3%
Operating Margin
+3.6%
Net Margin
-2.6%
EPS Growth
+62.0%
Financial Health
Cash/Price Ratio
+10.1%
Current Ratio
1.3x
Debt/Equity
0.0x
ROE
-16.9%
ROA
-5.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Clover Health Investments, Corp. (CLOV) Business Model
About Clover Health Investments, Corp.
What They Do
Provides Medicare Advantage plans using technology.
Business Model
The company operates in the insurance segment by offering Medicare Advantage plans, specifically PPO and HMO options. It generates revenue through premiums paid by members and leverages its proprietary Clover Assistant software to enhance patient outcomes and streamline chronic disease management, thereby improving the efficiency of care delivery.
Additional Information
Founded in 2014 and headquartered in Wilmington, Delaware, Clover Health focuses on integrating technology-driven preventive care into its services, which positions it as a significant player in the value-based healthcare market. The company aims to enhance the medical experience for Medicare-eligible individuals through data-informed insights.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
570
CEO
Mr. Andrew Toy
Country
United States
IPO Year
2021
Website
www.cloverhealth.comClover Health Investments, Corp. (CLOV) Latest News & Analysis
Latest News
Quick Summary
Clover Health Investments Corp (NASDAQ:CLOV) reported disappointing quarterly results, leading Jim Cramer to suggest investors should consider a speculative approach.
Why It Matters
Clover Health's poor quarterly results indicate potential volatility and risk, suggesting investors may need to adopt a speculative approach to trading the stock.
Source: Benzinga
Market Sentiment:
Neutral
Quick Summary
Clover Health Investments, Corp. (CLOV) held its Q1 2026 earnings call, providing insights into financial performance and business updates for investors.
Why It Matters
Clover Health's Q1 2026 earnings call reveals financial performance and strategic direction, influencing stock valuation, investor sentiment, and potential growth prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Clover Health Reports First Quarter 2026 Results
1 month ago
Quick Summary
Clover Health reported Q1 2026 GAAP net income of $27M, a $29M improvement YoY. Revenues rose 62% to $749M, with Medicare Advantage membership up 51% to 155,773. Guidance for full year 2026 remains strong.
Why It Matters
Clover Health's significant revenue and membership growth, alongside positive GAAP Net Income, signals strong operational performance and potential for continued profitability, enhancing investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CLOV reported a 62% revenue growth in Q1, driven by an increase in Medicare Advantage membership and improved profitability from AI-driven care initiatives.
Why It Matters
CLOV's 62% revenue growth and increased Medicare Advantage membership signal strong demand and effective operations, potentially enhancing investor confidence and driving stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Clover Health Investments (CLOV) reported Q3 earnings of $0.07 per share, matching estimates and up from $0.05 per share a year earlier.
Why It Matters
Clover Health's earnings match expectations and show year-over-year growth, indicating stability and potential for future gains, which can positively influence investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Butterfly Network, Inc. (BFLY) reported a quarterly loss of $0.03 per share, better than the estimated loss of $0.04, and an improvement from a loss of $0.06 per share a year prior.
Why It Matters
Butterfly Network's smaller-than-expected loss signals potential improvement in financial performance, which may boost investor confidence and impact stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About CLOV Stock
What is Clover Health Investments, Corp.'s (CLOV) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Clover Health Investments, Corp. (CLOV) has a median price target of $3.50. The highest price target is $4.20 and the lowest is $2.75.
Is CLOV stock a good investment in 2026?
According to current analyst ratings, CLOV has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLOV stock?
Wall Street analysts predict CLOV stock could reach $3.50 in the next 12 months. This represents a -8.6% decrease from the current price of $3.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Clover Health Investments, Corp.'s business model?
The company operates in the insurance segment by offering Medicare Advantage plans, specifically PPO and HMO options. It generates revenue through premiums paid by members and leverages its proprietary Clover Assistant software to enhance patient outcomes and streamline chronic disease management, thereby improving the efficiency of care delivery.
What is the highest forecasted price for CLOV Clover Health Investments, Corp.?
The highest price target for CLOV is $4.20 from Richard Close at Canaccord Genuity, which represents a 9.7% increase from the current price of $3.83.
What is the lowest forecasted price for CLOV Clover Health Investments, Corp.?
The lowest price target for CLOV is $2.75 from at , which represents a -28.2% decrease from the current price of $3.83.
What is the overall CLOV consensus from analysts for Clover Health Investments, Corp.?
The overall analyst consensus for CLOV is neutral. Out of 2 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $3.50.
How accurate are CLOV stock price projections?
Stock price projections, including those for Clover Health Investments, Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 7:12 AM UTC